Plain-English translation of NCT06498167 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a safety monitoring study for Rinvoq (), a medication used to treat rheumatoid arthritis, psoriatic arthritis, and several other inflammatory conditions. Researchers want to understand what side effects patients experience when taking this medication in real-world settings—outside of controlled clinical trials. The study is being run by Portuguese health authorities to make sure the medication remains safe for patients who need it.
Although this medication has been approved and used for several years, health authorities want to continue monitoring it carefully to catch any uncommon or serious side effects that might not have appeared during initial testing. This ongoing safety watch helps doctors and patients make informed decisions about using the treatment.
You likely qualify if…
You likely don't qualify if…
If you join, researchers will contact you by phone to ask questions about your health and any side effects you've experienced while taking the medication. The study uses information from both current and past medical records to build a complete picture of how the treatment is working in real patients. There is no new medication to take—you simply continue taking what your doctor prescribed while sharing your health experiences with the research team.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Portugal
Sponsor
Universidade do Porto
Collaborators
INFARMED - Autoridade Nacional do Medicamento e Produtos de Saúde, I.P., Unidade de Farmacovigilância do Porto
Enrollment target
~150 participants
Started
July 2024
Primary completion
October 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Inês Ribeiro Vaz, PharmD, MPH, PhD
Universidade do Porto
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.